<DOC>
	<DOC>NCT02739984</DOC>
	<brief_summary>The purpose of this study is to evaluate the effect of 12 weeks of subcutaneous evolocumab taken monthly compared with subcutaneous placebo taken monthly on low density lipoprotein cholesterol (LDL-C) in subjects with type 2 diabetes mellitus and high blood cholesterol on a maximally tolerated oral dose of statin of at least moderate-intensity.</brief_summary>
	<brief_title>A Study in Subjects With Type 2 Diabetes Mellitus With Hypercholesterolemia/Mixed Dyslipidemia</brief_title>
	<detailed_description>This study will enroll adult subjects (greater than or equal to 18 years of age) with type 2 diabetes mellitus and elevated LDL-C or non-HDL-C levels on a stable, maximally tolerated statin dose of at least moderate-intensity at signing of the informed consent; statin therapy must remain unchanged during screening and the remainder of the study. Subjects must have hemoglobin A1c (HbA1c) &lt; 10%, must have been receiving pharmacologic treatment for diabetes mellitus for greater than or equal to 6 months prior to screening, with stable diabetes therapy prior to randomization to investigational product (IP) and not expected to change throughout the duration of study participation.</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Dyslipidemias</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>Male or female ≥18 years, Type 2 Diabetes Mellitus, Hemoglobin A1c &lt;10%, Stable Diabetes Therapy, Must be on maximally tolerated dose of statin of at least moderate Intensity, Fasting triglycerides ≤ 600 mg/dL, Not at LDLC or NonHDLC goal. Moderate to severe renal dysfunction, Uncontrolled hypertension, Persistent active liver disease or hepatic dysfunction, Has taken a cholesterylester transfer protein inhibitor in the last 12 months, Myocardial infarction, unstable angina, percutaneous coronary intervention, coronary artery bypass graft or stroke within 3 months prior to randomization</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>diabetes</keyword>
	<keyword>type 2 diabetes</keyword>
	<keyword>high blood cholesterol</keyword>
	<keyword>hypercholesterolemia</keyword>
	<keyword>mixed dyslipidemia</keyword>
	<keyword>high cholesterol</keyword>
	<keyword>statin intolerant</keyword>
</DOC>